Currently, clinicians face a dilemma regarding the standard second‐line treatment of PD‐1 inhibitor monotherapy for advanced ESCC, as patients with a good performance status achieve a mOS of only 7.2–10.9 months [18, 20, 22, 30, 31]. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.